



Feel the
difference
with HTL inside



Pharmaceutical Grade Hyaluronic Acid & Biopolymers for premium medical products



For over 30 years, HTL Biotechnology has been developing products that make a difference. By offering the world a platform of pharmaceutical-grade solutions built around biopolymers, we unleash the potential of Hyaluronic Acid and DNA to serve the players who want to transform the health and well-being of patients worldwide.

We guarantee the absolute conformity of all our products to the highest standards of quality and good manufacturing practice. All our products are GMP-compliant. Thanks to our 64 000 sqm production site, based in France, we are able to respond to all our customers' requests, without ever suffering a break in the supply chain. For HTL, confidence means delivering the right product, at the right time, in the right quantity.



At HTL Biotechnology, innovation is in our DNA. Our in-depth knowledge of biopolymers and their production enables HTL Biotechnology to constantly offer new products, responding to the latest therapeutic applications and new customer needs.

Our ambition is to continue building the future of medicine and the biopolymer market.

Together, we are striving for excellence to improve the health and well-being of patients »

François Fournier,
CEO of HTL Biotechnology





30 years
of expertise



A PIONEER & A GLOBAL COMPANY

HTL Biotechnology is the pioneer in the responsible development and production of pharmaceutical grade biopolymers, used to develop life-changing treatments for millions of patients worldwide.

Our mission is to unleash the potential of Hyaluronic Acid and biopolymers.

For over 30 years, our teams have been developing and perfecting a pharmaceutical-grade biopolymer platform that provides customized solutions to pharmaceutical laboratories and medical device manufacturers worldwide in therapeutic areas such as Ophthalmology, Rheumatology, Dermatology and Medical Aesthetics.



More than
100
clients

In
30
countries



400 million+
syringes containing
HTL's Hyaluronic Acid have been
safely used since 2006



A HISTORY & A SET OF VALUES

Excellence

From the sourcing of our products to our partnerships of excellence, we do our utmost to guarantee the best possible service to our customers and partners.

Responsability

We reliably supply our customers with high-quality, tailor-made products and solutions that perfectly meet their requirements.

1977

Foundation of Javenech, a biotechnology research lab committed to human health

1992

Foundation of HTL Biotechnology

1992-2006

Pioneer in Hyaluronic Acid production by bacterial fermentation

2007-2016

HTL Biotechnology becomes **a global player** in injectable grade Hyaluronic Acid

2017

Investments in large R&D and Production projects

Pioneering

Today, all over the world, we continue to work with our customers and partners to develop innovative, high-performance solutions to meet unmet medical needs using our biopolymers platform.

Team spirit

For more than 30 years, we have been developing a relationship of trust and working hand in hand with each of our customers to provide them with a personalized approach that is as close as possible to their needs.

HTL : A pioneer for 30 years & for years to come

The HTL Biotechnology of the future means :

- a global expansion, from the United States to Asia, while strengthening our teams in France,
- an ever-increasing number of applications for our biopolymers,
- the constant creation of new innovative products thanks to our Innovation and R&D investments.

2019

Fermentation-based production of new biopolymers of medical interest

2020

Opening of Paris office
Launch of a LabCom for biomaterials

2021

Opening of the new GMP manufacturing facility HTL4
Opening of US and Asia offices
First strategic partnership on functionalization

2022

First investment in a biotechnology company

2023

New GMP chemistry facility dedicated to Functionalized Biopolymers



Our ambition is to continue to build the future of medicine and the biopolymer market

OUR PRODUCTS

Product Portfolio

Pharma Grade Hyaluronic Acid

Sodium DNA

Polydeoxiribonucleotide (PDRN / PN)

45 years track record in DNA production.

Providing DNA for both topical and injectable applications, with a very low level of impurities.

Innovation Portfolio

Heparosan

Heparosan is a glycosaminoglycan, a naturally occurring biopolymer, produced by HTL by non-animal origin. Heparosan has a structure and basic functionalities that are very close to those of Hyaluronic Acid, and displays additional functionalities.

Oligo HA

HA oligomers and ultra-low molecular weight Hyaluronic Acid are increasingly popular to modulate rheological or biological effects.

Building upon our 30 years of experience manufacturing pharmaceutical Hyaluronic Acid, we are expanding our range to support medical innovations worldwide.

Functionalized Biopolymers Services

HTL Biotechnology offers expert guidance and support to companies venturing into the industrial production of a modified Hyaluronic Acid compound, ensuring transparent and efficient processes.

Providing solutions for :



Ophthalmology

- ▶ Cataract surgery
- ▶ Eye drops



Aesthetics

- ▶ Dermal filler
- ▶ Skin rejuvenation



Dermatology

- ▶ Wound healing



Rheumatology

- ▶ Visco-supplementation

Premium
**QUALITY
HYALURONIC
ACID**

Our pharmaceutical grade Hyaluronic Acid of non-animal origin has been recognized on the market for its premium quality. Our wide range of molecular weight and flexible supply support the evolving needs of the medical devices and pharmaceutical industries.

THE WIDEST HA OFFER


From very low to very high
Intrinsic Viscosity

**Our Hyaluronic Acid
is CEP, USDMF, JDMF,
KDMF registered.**

1 GLOBAL PROVIDER
OF INJECTABLE
PHARMA-GRADE
HYALURONIC ACID
BY BIOPRODUCTION



CONTACT US FOR MORE INFORMATIONS



A UNIQUE FRENCH KNOW-HOW BASED ON 30 YEARS OF EXPERTISE IN BIOPOLYMER PRODUCTION

Located in Brittany, France our production site of 64 000 sqm hosts state-of-the-art facilities :

- ▶ 2 independant production units of Hyaluronic Acid
- ▶ 2 production units of DNA (cosmetics & pharmaceuticals)
- ▶ 1 R&D Laboratory
- ▶ GMP Pilot Facilities
- ▶ GMP Chemistry Laboratory
- ▶ 1 Quality Control Laboratory

HTL Biotechnology has developed industrial facilities to ensure supply to its customers, while meeting the growing demand for Hyaluronic Acid and DNA, and is investing to double its DNA production capacity over the next few years.



Quality is our Identity

HTL Biotechnology guarantees the absolute conformity of all its products to the highest standards of quality and good manufacturing practices. All our products are **GMP-compliant**.

Our commitment to safety and excellence is easily demonstrated : no batch recalls in three decades, audited and certified by the **FDA** (USA), **ANSM** (European Union), **PMDA** (Japan) and **MFDS** (Korea).





At HTL Biotechnology, innovation is at the heart of our strategy.

Our ambition is to innovate for the benefit of our customers and their patients through the development of increasingly innovative and high-performance biopolymers platforms.

Our facilities are equipped with the latest technology and state-of-the-art equipments, enabling us to analyse, modify, and improve our biopolymers in depth. Whether perfecting the properties of existing biopolymers or paving the way for the development of new ones, our specialist teams work seamlessly together to drive innovation forward.

We are convinced that biopolymers have infinite applications in many therapeutic areas. There are many modifications of their properties and new biopolymers to be explored and developed, which gives us infinite opportunities. »




Anne-Laure Gaudry,
Head of Innovation and R&D



DRIVING SCIENTIFIC EXCELLENCE IN BIOPOLYMERS

Our expertise in the development of new biopolymers and functionalizing Hyaluronic Acid is supported by :



1 000 sqm
of laboratory space



700 sqm
pilot plants to scale up from lab to cGMP



15 %
of the HTL workforce



Thanks to our R&D strategy, we are exploring new therapeutic applications for our biopolymers in areas of breakthrough innovation such as



Drug delivery



Microneedles



Regenerative medicine





BEYOND TOGETHER, SUSTAINABLY

HTL Biotechnology is committed to working with its customers and stakeholders to reduce its environmental footprint in order to combat climate change and preserve resources.

- ▶ Reduce and control our water consumption
- ▶ Control aqueous and atmospheric discharges and prevent risks of air, water and soil pollution
- ▶ Reduce our fossil fuel consumption (decarbonisation)
- ▶ Set up management system to reduce our environmental footprint
- ▶ Eco-design our processes and products
- ▶ Sort, recycle, recover our waste
- ▶ Take action to preserve ecosystems
- ▶ Optimise our supply chain with our suppliers and service provider



ECOVADIS GOLD RATING



CERTIFIED ISO 14001

HTL Biotechnology wants to be responsible for its impact





Reduce greenhouse gas emissions by 30% per kilo of Hyaluronic Acid produced by 2026




Recycle and reuse 30% of our waste by 2025



Reduce water consumption per kilo of Hyaluronic Acid produced by 20% by 2025



WE ARE WORLDWIDE



Export to
30
countries

5
Offices
around
the world



Meet us

Headquarters
and industrial site:
7 Rue Alfred Kastler
ZI de l'Aumallerie
35133 Javené, France

Contact us

+33 (0)2 99 99 37 37
contact@htlbiotech.com

Follow us



[htlbiotech.com](https://www.htlbiotech.com)

